fujirebio lumipulse g kits  (Fujirebio Inc)

Journal: medRxiv

Article Title: Brain Damage During New-Onset Refractory Status Epilepticus

doi: 10.1101/2025.08.05.25332982

Figure Lengend Snippet: (A–C) Levels of serum neurofilament light chain (NfL, A ), cerebrospinal fluid (CSF) total Tau (B) , and serum glial fibrillary acidic protein (GFAP, C ) in patients during NORSE, after NORSE, with autoimmune encephalitis, and in internal and external epilepsy cohorts with brief seizures. Horizontal lines represent 95% confidence intervals (upper bounds shown). Asterisks indicate statistically significant differences between measurements during NORSE and pairwise comparisons with all other groups. CSF total Tau was not available for the external epilepsy cohort. (D–F) Associations between fluid biomarkers during NORSE and clinical variables: (D) Higher NfL levels were associated with worse long-term functional outcome (modified Rankin Scale); (E) Total Tau was highest when measured early in the SE course; (F) GFAP correlated with greater SE severity. (G–I) Associations between fluid biomarker levels during NORSE and the rate of brain atrophy. Brain maps display regions where higher biomarker levels were associated with greater GMV loss (blue = atrophy; red = thickness/volume increase). Below each map, GMV loss estimates are shown using linear mixed-effects models. Continuous biomarker levels were dichotomized at the median for visualization only; all statistical analyses were based on continuous data. NORSE, new onset refractory status epilepticus; NfL, neurofilament light chain; GFAP, glial fibrillary acidic protein; mRS, modified Rankin Scale; SE, status epilepticus; T, thalamus; H, hippocampus; A, amygdala; Pa, pallidum; Pu, putamen; FWE, family-wise error .

Article Snippet: CSF total Tau concentrations were quantified using the Lumipulse G Total Tau assay (Fujirebio Inc., Tokyo, Japan).

Techniques: Functional Assay, Modification, Biomarker Discovery

Journal: medRxiv

Article Title: Brain Damage During New-Onset Refractory Status Epilepticus

doi: 10.1101/2025.08.05.25332982

Figure Lengend Snippet: (A, F) Selected axial slices from the first, third, and fifth MRI scans performed during NORSE in each case. Progressive enlargement of cerebrospinal fluid spaces, consistent with brain atrophy, is evident in the final scan compared to the initial one. (B, G) Relative changes in brain morphometry over time from SE onset, referenced to the first available MRI scan. Each square represents one MRI, with scans from the same individual connected by lines. Both cases showed rapid grey matter volume loss, particularly affecting subcortical structures, with minimal change in white matter volume. (C, H) Annualized whole-brain morphometric changes between the first and last MRI during NORSE, mapped onto cortical and subcortical templates. Brain shrinkage was bilateral and widespread in both cases. (D, I) Longitudinal trajectories of fluid biomarkers of neurodegeneration (neurofilament light chain, NfL; glial fibrillary acidic protein, GFAP; Total Tau), referenced to the internal epilepsy cohort mean (log-scale, k-fold increase from epilepsy mean). (E, J) Neuropathological findings compared with a representative healthy cortex (bottom panel). In Case 1 (E) , cortical tissues showed decreased numbers of neuronal nuclear antigen (NeuN) positive neurons with preserved layering with Luxol fast blue staining and marked GFAP-positive reactive astrogliosis. In Case 2 (F) there were several fragments of cerebral cortex and subcortical white matter with reduced neuronal numbers and reactive astrogliosis. NORSE, new onset refractory status epilepticus; NfL, neurofilament light chain; GFAP, glial fibrillary acidic protein; CSF, cerebrospinal fluid; neuronal nuclear antigen, NeuN; T, thalamus; H, hippocampus; A, amygdala; Pa, pallidum; Pu, putamen .

Article Snippet: CSF total Tau concentrations were quantified using the Lumipulse G Total Tau assay (Fujirebio Inc., Tokyo, Japan).

Techniques: Staining